Trials / Unknown
UnknownNCT04325711
A Study of CSPCHA131 in Patients With Advanced Solid Tumor
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of CSPCHA131 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study was designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of CSPCHA131 alone or plus chemotherapy in patients with advanced solid tumors.
Detailed description
This is a dose escalation and expansion study with the aim to evaluate and characterize the tolerability and safety profile of CSPCHA131 alone (Stage I) or plus chemotherapy (Stage II) in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CSPCHA131 | CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle. |
Timeline
- Start date
- 2020-04-24
- Primary completion
- 2021-04-12
- Completion
- 2021-04-12
- First posted
- 2020-03-30
- Last updated
- 2021-01-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04325711. Inclusion in this directory is not an endorsement.